Delivering medical breakthroughs
for Diabetes & Obesity

Management & Board of Directors

Management

W. Blair Geho

W. Blair Geho serves as Diasome’s Chief Science Officer, and he is also a founder of the Company and a member of the Board of Directors. Dr. Geho is an alumnus of CWRU, (Ph.D. in Pharmacology and M.D.) and was a member of the CWRU School of Medicine Faculty in the departments of Pharmacology and Surgery for several years.  He then became the first research-trained physician at the Procter and Gamble Company in Cincinnati.  At P&G, Dr. Geho led the development of the first bis-phosphonate compounds for bone imaging (Osteoscan®) and metabolic bone disease (Didronel®) from preclinical studies, through clinical trials and FDA approval.  Bis-phosponates are the class of drugs used for treating osteoporosis and cancer-related bone pain. Dr. Geho established P&G’s pharmaceutical research division. Following P&G, Dr. Geho founded and led four biotechnology firms, serving as Chief Science Officer and CEO.  As an entrepreneur, Dr. Geho has raised approximately forty million dollars to develop various new pharmaceutical products.  The most recent activity has been the development of liver-targeted insulin, for oral and injection use in diabetics.  The FDA has approved these products for phase 3, or final testing, prior to receiving FDA approval. Beginning in December 2011, Dr. Geho became one of two Chief Translational Officers for the CWRU School of Medicine, leading the effort to commercialize new discoveries in the School of Medicine. 

Robert Geho

Robert Geho is a co-founder and CEO of Diasome Pharmaceuticals, Inc.   In his role at Diasome, he leads the management and strategic direction of the Company’s targeted insulin therapies, novel Type 2 diabetes technology, and oral therapy for obesity.  In addition to his responsibilities at Diasome, he is a co-founder and director of SDG, Inc., a nanotechnology therapeutics company that is an Equity Partner Company of the Cleveland Clinic Foundation in Cleveland, Ohio. Mr. Geho has led or co-led multiple rounds of financing for several biotechnology companies, and he has been a key participant in the formation of multiple life sciences focused companies. He received both his undergraduate degree and an MBA from Case Western Reserve University. Mr. Geho also serves as a member of the board of directors of the Diabetes Hands Foundation.

Helga Kautsky, CPA

Helga Kautsky, CPA, is Diasome’s Chief Financial Officer.  Ms. Kautsky is also President and Founder of Pickering Financial Ltd., a firm that provides interim or part time CFO/Controller level financial and administrative services for early stage and medium size businesses. Prior to founding Pickering Financial, Helga served as Director of Financial Planning at SmithKline Beecham, and Financial Planning Manager for the former Astra-Merck JV, where she was responsible for managing the budgeting, forecasting and strategic planning processes. She began her career in public accounting, with Price Waterhouse where she obtained her CPA certification.  She obtained her B.S. in Accounting from Lehigh University.

 

Board of Directors

Richard E. Caruso, PH.D.

Richard E. Caruso, PH.D. is Diasome’s the Chairman of the Board of Directors at Diasome. He founded Integra Life Sciences in 1989 and served as the Company’s CEO and President from its founding until 1997, its Chairman from March 1992 until January 2012, and as a director since March 1992. Dr. Caruso is currently the President and a member of The Provco Group, a venture and real estate investment company, an advisor to Quaker BioVentures, a medical venture capital financial investor, a member of the Board of Directors of Camel City Solar, LLC, a development stage solar energy company, and an advisor to NewSpring Capital and ePlanet Ventures II, both diversified venture capital financial investors. From 1969 to 1992, Dr. Caruso was a principal of LFC Financial Corporation, a project finance company, where he was also a director and Executive Vice President. In 2006, Dr. Caruso was named the Ernst and Young National Entrepreneur of the Year for the United States. Dr. Caruso is on the Board of Susquehanna University, The Baum School of Art and the Uncommon Individual Foundation (Founder). He received a B.S. degree from Susquehanna University, an M.S.B.A. degree from Bucknell University, a Ph.D. degree from the London School of Economics, University of London (United Kingdom) and an honorary Ph.D. degree in medical engineering from Drexel University.

W. Blair Geho

W. Blair Geho serves as Diasome’s Chief Science Officer, and he is also a founder of the Company and a member of the Board of Directors. Dr. Geho is an alumnus of CWRU, (Ph.D. 1964 and M.D. 1966) and was a member of the CWRU School of Medicine Faculty in the departments of Pharmacology and Surgery for several years.  He then became the first research-trained physician at the Procter and Gamble Company in Cincinnati.  At P&G, Dr. Geho led the development of the first bis-phosphonate compounds for bone imaging (Osteoscan®) and metabolic bone disease (Didronel®) from preclinical studies, through clinical trials and FDA approval.  Bis-phosponates are the class of drugs used for treating osteoporosis and cancer-related bone pain. Dr. Geho established P&G’s pharmaceutical research division. Following P&G, Dr. Geho founded and led four biotechnology firms, serving as Chief Science Officer and CEO.  As an entrepreneur, Dr. Geho has raised approximately forty million dollars to develop various new pharmaceutical products.  The most recent activity has been the development of liver-targeted insulin, for oral and injection use in diabetics.  The FDA has approved these products for phase 3, or final testing, prior to receiving FDA approval. Beginning in December 2011, Dr. Geho became one of two Chief Translational Officers for the CWRU School of Medicine, leading the effort to commercialize new discoveries in the School of Medicine. 

Robert Geho

Robert Geho is a co-founder and CEO of Diasome Pharmaceuticals, Inc., a privately held company focused on the clinical development and commercialization of Phase 3 ready, hepatic targeted insulin therapies for the treatment of Type 1 and Type 2 diabetes, as well as other novel treatment strategies for metabolic diseases. As Chief Business Officer and then as CEO, Mr. Geho has led each of Diasome’s rounds of funding, and he has participated as a member of the Company’s executive management team in the design and execution of its injectable and oral insulin programs. In addition to his responsibilities at Diasome, he is a co-founder and director of SDG, Inc., a nanotechnology therapeutics company that is an Equity Partner Company of the Cleveland Clinic Foundation in Cleveland, Ohio. Mr. Geho has led or co-led multiple rounds of financing for several biotechnology companies, and he has been a key participant in the formation of a variety of life sciences focused companies. He received both his undergraduate degree and an MBA from Case Western Reserve University. Mr. Geho also serves as a member of the board of directors of the Diabetes Hands Foundation.

Frank McCaney

Frank McCaney is a member of Diasome’s Board of Directors and was Founder and CEO of Nitric BioTherapeutics, a venture backed medical technology company, from 2006 until 2012.  Prior to Nitric Bio, he was an Executive of Viasys Healthcare, Inc. (VAS:NYSE) and had a lead role in spinning Viasys out of Thermo Electron Corporation (TMO:NYSE).  While at Thermo Electron, he co-pioneered relationships with The Battelle Institute and MIT.  Mr. McCaney is the CEO and a member of the Board of Directors of Corpak MedSystems, Inc.

Thomas McDonald

Thomas McDonald is a member of Diasome’s Board of Directors and is the founder, President, and CEO of McDonald Partners LLC, a full service brokerage and investment advisory firm located in Cleveland, Ohio.  Prior to founding McDonald Partners, he served as President and CEO for Wayne Hummer Investments in Chicago, Illinois from 2003 – 2005.  Mr. McDonald had total responsibility for the P&L of the company and was responsible for growing the company through the addition of high quality financial advisors to service high net worth clients of the parent company’s banks.  Prior to joining Wayne Hummer, he spent twelve years with McDonald Investments in Cleveland, Ohio, where he began as director of sales development and progressed in responsibility to ultimately become director of the Private Client Group.  Under Mr. McDonald’s leadership, the firm successfully transitioned from almost entirely transaction-based revenues to over 60% fee-based revenues.  After KeyBank acquired McDonald Investments, he was responsible for growing the firm and increased revenues from just over $100 million to over $600 million.  Among other industry activities, Mr. McDonald is a member of the Security Industry Association’s Public Trust and Confidence Committee.

 

Scientific Advisory Board

Alan Cherrington, PhD

Alan Cherrington, PhD, is the Emeritus Chairman of the Department of Molecular Physiology and Biophysics at Vanderbilt University, and he holds Professorships in both the Department of Molecular Physiology and Biophysics and in the Department of Medicine at Vanderbilt.  A recognized authority on the liver and glucose metabolism, Dr. Cherrington served as President of the American Diabetes Association from 2004 – 2005, and he is the 2005 recipient of the Banting Medal for Service from the American Diabetes Association.  Dr. Cherrington received his undergraduate degree in Biology from the University of New Brunswick and his PhD in Physiology from the University of Toronto, where he worked with Dr. Mladen Vranic.

Alexander Fleming, MD

Alexander Fleming, MD, is an endocrinologist who was at Vanderbilt and NIH before heading FDA’s clinical review of diabetes and other metabolic drugs. At FDA, he was responsible for approval of metformin and the first statin, insulin analog, and other regulatory landmarks. He also chaired professional education in the Center for Drugs, often represented FDA internationally, and was assigned to the World Health Organization in Geneva. Dr. Fleming founded in 2001 and continues to lead Kinexum, a strategic services firms that has helped over 100 large and small companies and foundations in the cardiometabolic, oncology, GI, immunology and dermatology domains. Dr. Fleming frequently speaks internationally on new therapeutic targets and indications and innovative clinical trial designs and regulatory approaches.

Marc Penn, MD, PhD, FACC

Marc Penn, MD, PhD, FACC, is a cardiologist and Director of Research at the Summa Cardiovascular Institute in Akron, Ohio and Professor of Medicine and Integrative Medical Sciences at Northeast Ohio Medical University where he leads the Skirball Laboratory for Cardiovascular Cellular Therapeutics.  From 2000 until 2011, Dr. Penn was a staff cardiologist at the Cleveland Clinic, where he served as the Director of the Coronary Intensive Care Unit and Director of the Experimental Animal Laboratory. Dr. Penn completed his undergraduate and postgraduate work at Case Western Reserve University completing a Ph.D. in Biomedical Engineering in 1989 and Doctor of Medicine in 1994.

Arthur Rubenstein, MBBCh

Arthur Rubenstein, MBBCh, is a Professor of Medicine in the Division of Endocrinology, Diabetes, and Metabolism and the former Dean at the University of Pennsylvania’s Perelman School of Medicine. Previously, Dr. Rubenstein was Dean and Gustave L. Levy Distinguished Professor at the Mount Sinai School of Medicine in New York and chairman of the Department of Medicine at the University of Chicago. Dr. Rubenstein is a distinguished member of the American Academy of Arts and Sciences, the American Association for the Advancement of Science, and the Institute of Medicine, and he is a recognized authority in diabetes research.  His research, together with Dr. D. Steiner, in diabetes was instrumental in the development of the first commercial production technology for human insulin.